Creatine Does Not Cause Hair Loss, First Controlled Trial Confirms

The claim that creatine supplementation causes hair loss has circulated widely among athletes and fitness enthusiasts, largely fueled by a single 2009 study suggesting short-term creatine use elevated DHT — the androgen primarily responsible for androgenetic alopecia. Despite this, no study had ever directly measured hair follicle health in creatine users, leaving the question unresolved. This trial was designed to close that gap.

Forty-five resistance-trained males aged 18–40 were recruited and randomized in a double-blind fashion to receive either 5 g/day of creatine monohydrate or an identical-appearing maltodextrin placebo for 12 weeks. Participants maintained habitual diets and performed at least three resistance training sessions per week. Compliance was monitored via daily WhatsApp check-ins and collection of empty supplement packets. Thirty-eight participants completed the study (19 per group).

Blood samples collected at baseline and week 12 measured total testosterone, free testosterone, DHT, creatinine, and eGFR. Hair follicle health was assessed by board-certified dermatologists using the FotoFinder dermoscopy system and trichogram testing, focusing on the vertex scalp — the region most susceptible to androgenetic alopecia. Outcomes included hair density, follicular unit count, and cumulative hair thickness. Repeated-measures ANOVA with sensitivity analysis for outliers was used throughout.

Neither DHT levels nor the DHT-to-testosterone ratio differed between groups at any time point, and there were no group-by-time interactions for any hormonal or hair-related outcome. Both groups showed increases in total testosterone and decreases in free testosterone over the 12-week period, but these changes were not linked to supplementation. Critically, all three objective hair follicle metrics — density, follicular unit count, and cumulative thickness — remained statistically identical between the creatine and placebo groups.

These findings carry meaningful implications for the millions of people who use creatine globally. The persistent fear of hair loss has likely deterred some individuals from benefiting from one of the most well-validated sports supplements available. This trial, the first to directly examine hair follicle physiology in response to creatine, provides strong reassurance that a standard maintenance dose of 5 g/day does not adversely affect androgenic hair loss pathways over a clinically meaningful 12-week window. Limitations include an all-male sample, a single dose tested, and the absence of longer follow-up beyond 12 weeks.